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Sir,
We read the recent study by Newton et al (2005) with great
interest. Presently, we offer a few thoughts on what their results
suggest about the role of BK virus in cancer.
First, haemorrhagic cystitis and BK nephropathy in transplant
patients are the principal disease entities for which BK virus has
been implicated (Hirsch, 2005). We ask, how do the antibody titers
of the cancer patients and controls compare to transplant patients
diagnosed with BK nephropathy or haemorrhagic cystitis? It would
be informative to know whether antibody titers in patients with
active BK nephropathy are within the range reported for patients
with carcinoma.
Similarly, how do antibody titers in BK nephropathy patients
change with treatment and resolution of BK infection? Perhaps
antibody titers decline following resolution of the active BK
infection to levels comparable to those reported by Newton et al
(2005). Consider a cancer patient with a history of prior BK
infection whose antibody titers were previously high, but now have
declined. In such an instance, BK virus may be implicated in
carcinogenesis, although the antibody titers at the time of this
study have returned to the range of normal individuals. Certainly,
a study documenting how antibody titers in patients with BK
nephropathy change over time would be enlightening.
Infection with polyomavirus (PV) may both disrupt the function
of tumour-suppressor proteins p53 and pRb (Reich and Levine,
1982; DeCaprio et al, 1988; Bollag et al, 1989; Dyson et al, 1990;
Harris et al, 1998; Pipas and Levine, 2001). As the PV infection is
cleared, the ability of the cell to respond appropriately to DNA
damage may remain impaired. The cells are then transformed,
although the active phase of infection has resolved. We suggest,
based on this ‘hit-and-run’ mechanism, that the absence of elevated
titers does not exclude a role for BK virus in carcinogenesis.
Nonetheless, the ‘hit-and-run’ mechanism is difficult to defend
experimentally. How does one find evidence for an infection that
has resolved? We anticipate that this may become an area of active
research in the near future.
Finally, Weinreb et al (2006) identified a population of patients
with PV-infected ‘decoy’ cells seen on urine cytologic analysis. The
incidence of bladder carcinoma in this population was significantly
higher than in patients receiving urine cytologic analysis but
lacking any such infected cells. Their data suggests an association
of PV infection with bladder carcinoma. Did any patients in Dr
Newton’s study have urine cytologic analyses revealing such ‘decoy’
cells? Is there any correlation between the presence of such virally
infected cells and antibody titers? The detection of ‘decoy’ cells may
be more closely associated with carcinoma than antibody titers.
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